

One aspect as reported herein is the antibody as reported herein for use in depleting B-cells.

5 One aspect as reported herein is the use of the antibody as reported herein in the manufacture of a medicament for the treatment of a disease associated with pathologic increase of B-cells, an inflammatory disease, an autoimmune disease, rheumatoid arthritis, lupus, psoriasis, or a bone disease.

One aspect as reported herein is the use of the antibody as reported herein in the manufacture of a medicament for the treatment of a B-cell cancer.

10 One aspect as reported herein is the use of the antibody as reported herein in the manufacture of a medicament for the depletion of B-cells.

In one embodiment the medicament is for the treatment of a B-cell cancer, an inflammatory disease, an autoimmune disease, rheumatoid arthritis, lupus, psoriasis, or a bone disease. In one embodiment the medicament is for the depletion of B-cells.

15 As reported herein is a method of treating an individual having a B-cell cancer comprising administering to the individual an effective amount of the antibody as reported herein.

20 As reported herein is a method of depleting B-cells in an individual comprising administering to the individual an effective amount of the antibody as reported herein.

As reported herein is a method for the manufacture of a medicament for the treatment of a disease comprising an antibody as reported herein. In one embodiment the disease is a B-cell cancer, an inflammatory disease, an autoimmune disease, rheumatoid arthritis, lupus, psoriasis, or a bone disease.

25 As reported herein is an isolated nucleic acid encoding the antibody as reported herein.

As reported herein is a host cell comprising the nucleic acid as reported herein.

30 As reported herein is a method of producing an antibody comprising culturing the host cell comprising the nucleic acid encoding the antibody so that the antibody is produced, recovering the antibody from the cell or the cultivation medium and purifying the antibody.

As reported herein is an immunoconjugate comprising the antibody as reported herein and a cytotoxic agent.

9. The antibody according to any one of claims 1 to 5 for use in the depletion of B-cells.
10. Use of the antibody according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a disease associated with pathologic increase of B-cells, an inflammatory disease, an autoimmune disease, rheumatoid arthritis, lupus, psoriasis, or a bone disease.
11. Use of the antibody according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a B-cell cancer.
12. Use of the antibody according to any one of claims 1 to 5 in the manufacture of a medicament for the depletion of B-cells.